CoChat
Cited by 171

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial

Open access
Anand, Atul, Lee, Kuan Ken, Chapman, Andrew R., Ferry, Amy V., Adamson, Phil D., Strachan, Fiona E., Berry, Colin, Findlay, Iain, Cruikshank, Anne, Reid, Alan, Collinson, Paul O., Apple, Fred S., McAllister, David A., Maguire, Donogh, Fox, Keith A.A., Newby, David E., Tuck, Chris, Harkess, Ronald, Keerie, Catriona, Weir, Christopher J., Parker, Richard A., Gray, Alasdair, Shah, Anoop S.V., Mills, Nicholas L., Alexander, Bill, Amoils, Shannon, Armstrong, Roma, Bularga, Anda, Croal, Bernard L., Doudesis, Dimitrios, Fischbacher, Colin M., Ford, Ian, Fujisawa, Takeshi, Harkess, Ronnie, Kimenai, Dorien M., Leslie, Stephen J., Linksted, Pamela, Lowry, Matthew T.H., MacDonald, Claire, Marshall, Lucy, Mendusic, Filip, Norrie, John, Sadat, Imran, Stables, Catherine L., Stevens, Jennifer, Stewart, Stacey D., Stirling, Laura, Taggart, Caelan, Wereski, Ryan, Young, Stephen · 2021 · Circulation

Abstract

Background: High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled out earlier, but the safety and efficacy of this approach is uncertain. We investigated whether an early rule-out pathway is safe and effective for patients with suspected acute coronary syndrome. Methods: We performed a stepped-wedge cluster randomized controlled trial in the emergency departments of 7 acute care hospitals in Scotland. Consecutive patients presenting with suspected acute coronary syndrome between December 2014 and December 2016 were included. Sites were randomized to implement an early rule-out pathway where myocardial infarction was excluded if high-sensitivity cardiac troponin I concentrations were <5 ng/L at presentation. During a previous validation phase, myocardial infarction was ruled out when troponin concentrations were <99th percentile at 6 to 12 hours after symptom onset. The coprimary outcome was length of stay (efficacy) and myocardial infarction or cardiac death after discharge at 30 days (safety). Patients were followed for 1 year to evaluate safety and other secondary outcomes. Results: We enrolled 31 492 patients (59±17 years of age [mean±SD]; 45% women) with troponin concentrations <99th percentile at presentation. Length of stay was reduced from 10.1±4.1 to 6.8±3.9 hours (adjusted geometric mean ratio, 0.78 [95% CI, 0.73–0.83]; P <0.001) after implementation and the proportion of patients discharged increased from 50% to 71% (adjusted odds ratio, 1.59 [95% CI, 1.45–1.75]). Noninferiority was not demonstrated for the 30-day safety outcome (upper limit of 1-sided 95% CI for adjusted risk difference, 0.70% [noninferiority margin 0.50%]; P =0.068), but the observed differences favored the early rule-out pathway (0.4% [57/14 700] versus 0.3% [56/16 792]). At 1 year, the safety outcome occurred in 2.7% (396/14 700) and 1.8% (307/16 792) of patients before and after implementation (adjusted odds ratio, 1.02 [95% CI, 0.74–1.40]; P =0.894), and there were no differences in hospital reattendance or all-cause mortality. Conclusions: Implementation of an early rule-out pathway for myocardial infarction reduced length of stay and hospital admission. Although noninferiority for the safety outcome was not demonstrated at 30 days, there was no increase in cardiac events at 1 year. Adoption of this pathway would have major benefits for patients and health care providers. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03005158.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.052380

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 171

Metadata

Authors
Anand, A., Lee, K. K., Chapman, A. R., Ferry, A. V., Adamson, P. D., Strachan, F. E., Berry, C., Findlay, I., Cruikshank, A., Reid, A., Collinson, P. O., Apple, F. S., McAllister, D. A., Maguire, D., Fox, K. A. A., Newby, D. E., Tuck, C., Harkess, R., Keerie, C., Weir, C. J., Parker, R. A., Gray, A., Shah, A. S. V., Mills, N. L., Alexander, B., Amoils, S., Armstrong, R., Bularga, A., Croal, B. L., Doudesis, D., Fischbacher, C. M., Ford, I., Fujisawa, T., Harkess, R., Kimenai, D. M., Leslie, S. J., Linksted, P., Lowry, M. T. H., MacDonald, C., Marshall, L., Mendusic, F., Norrie, J., Sadat, I., Stables, C. L., Stevens, J., Stewart, S. D., Stirling, L., Taggart, C., Wereski, R., & Young, S.
Venue
Circulation
Published
2021-06-08
Volume
143
Issue
23
Pages
2214-2224
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3138958193
Cited by
171
References
4
FWCI
17.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. https://app.cochat.ai/papers/10.1161/circulationaha.120.052380
The paper
Anand, A., Lee, K. K., Chapman, A. R., Ferry, A. V., Adamson, P. D., Strachan, F. E., Berry, C., Findlay, I., Cruikshank, A., Reid, A., Collinson, P. O., Apple, F. S., McAllister, D. A., Maguire, D., Fox, K. A. A., Newby, D. E., Tuck, C., Harkess, R., Keerie, C., . . . Young, S. (2021). High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.120.052380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.